The average one-year price target for Atea Pharmaceuticals (NasdaqGS:AVIR) has been revised to $10.20 / share. This is an ...

Investors are always looking for stocks that are poised to beat at earnings season and Atea Pharmaceuticals, Inc. AVIR may be one such company. The firm has earnings coming up pretty soon, and events ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Atea Pharmaceuticals, Inc. (AVIR) been one of those stocks ...

If you are looking to invest in Aviragen Therapeutics Inc’s (NASDAQ:AVIR), or currently own the stock, then you need to understand its beta in order to understand how it can affect the risk of your ...

VIENNA--(BUSINESS WIRE)--Studies performed in three animal models confirmed the safety and intensive immunogenicity of a new type of intranasal H5N1 influenza vaccine, according to the latest ...

Innovative vaccines for intranasal spray delivery or oral administration combine high efficacy with easy application. For the first time study data are available on the vaccine in its trivalent ...

Aceclofenac (Avir) is a nonsteroidal anti-inflammatory drug (NSAID), prescribed for fever and to relieve pain and swelling in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It ...